# Creatine Safety & Tolerability in Huntington's Disease

> **NCT01412151** · PHASE2 · COMPLETED · sponsor: **Massachusetts General Hospital** · enrollment: 10 (actual)

## Conditions studied

- Huntington's Disease (HD)

## Interventions

- **DRUG:** Creatine monohydrate

## Key facts

- **NCT ID:** NCT01412151
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-04
- **Primary completion:** 2011-11
- **Final completion:** 2011-11
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2018-03-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01412151

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01412151, "Creatine Safety & Tolerability in Huntington's Disease". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01412151. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*